Sentinel node total tumour load as a predictive factor for non-sentinel node status in early breast cancer patients – The porttle study
| Autor: | Ana Paula Correia, Mrinalini Honavar, Madalena Nogueira, Maria José Brito, Isabel Amendoeira, Arnaldo Machado, Patricia Pontes, José Luis Fougo, Bárbara Peleteiro, Ana Moura Gonçalves, Susana Marta, André Magalhães |
|---|---|
| Přispěvatelé: | Instituto de Saúde Pública da Universidade do Porto |
| Rok vydání: | 2020 |
| Předmět: |
Adult
Oncology medicine.medical_specialty Multivariate statistics Receptor ErbB-2 Breast Neoplasms 030230 surgery Logistic regression Metastasis Young Adult 03 medical and health sciences Breast cancer 0302 clinical medicine Internal medicine OSNA medicine Humans Cutoff Aged Retrospective Studies Aged 80 and over Sentinel Lymph Node Biopsy business.industry Carcinoma Ductal Breast Univariate Non sentinel node Non-sentinel node Middle Aged Sentinel node Prognosis medicine.disease Carcinoma Lobular Receptors Estrogen Lymphatic Metastasis 030220 oncology & carcinogenesis Female Surgery Lymph Nodes Receptors Progesterone Prediction business Follow-Up Studies |
| Zdroj: | Surgical Oncology. 32:108-114 |
| ISSN: | 0960-7404 |
| DOI: | 10.1016/j.suronc.2019.11.008 |
| Popis: | OSNA is a molecular assay for the detection of sentinel node metastasis. TTL emerged as a concept that seems to accurately predict the status of the NSN. Authors tried to confirm this motion. This is a retrospective and multicentric study that analyzed 2164 patients, 579 of whom had positive SN and completion AD. Logistic regression models were performed in order to identify a suitable cutoff to identify patients who benefit from AD. Univariate and multivariate regression analysis showed a relationship between TTL>30000 and the presence of NSN metastasis (OR 2.84, CI 1.99–4.08, p < 0.001). Logistic regression indicated that the cutoff of 30000 copies/μL better discriminates patients with NSN positivity and allows wide use of these criteria. This cutoff value may safely assist clinicians and patients to decide to proceed or not with an AD. There was no sponsorship. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect